Our current portfolio includes novel clinical-stage assets, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is exclusively licensed to Akebia and is being advanced in rare kidney disease. Olinciguat is a vascular sGC stimulator that Cyclerion intends to develop itself or out-license for cardiovascular diseases. Concurrently, we are also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments. In addition, Cyclerion holds 10 percent equity ownership in Tisento Therapeutics as part of an asset purchase agreement in which Tisento acquired the brain-penetrant sGC stimulators zagociguat and CY3018.
Looking for a particular Cyclerion employee's phone or email?
Cyclerion Questions
The Cyclerion annual revenue was $26 million in 2026.
Regina Graul is the CEO of Cyclerion.
5 people are employed at Cyclerion.
Cyclerion is based in Cambridge, Massachusetts.
The NAICS codes for Cyclerion are [3254, 541, 541712, 5417, 54, 325, 32, 54171].
The SIC codes for Cyclerion are [28, 283, 87, 873].
Top Cyclerion Employees
-
Regina Graul
Chief Executive Officer at Cyclerion
Boston, MA, US32 -
Michelle Hewitt
Associate Director, Medical Writing at Cyclerion
Somerville, MA, US13 -
Kenneth Tripp
Head of Biostatistics at Cyclerion
Boston, MA, US -
Alexia Vicente Cordero
Administrative Assistant at Cyclerion
San Diego, CA, US
Related Companies
